Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.

CONCLUSIONS: LSMEMs demonstrate that treatment with AVP-825 is associated with lower average migraine pain intensity and disability from 10 to 90 minutes and greater within-person consistency across multiple migraine attacks (reduced WPV) from 45 to 120 minutes post-dose compared to oral sumatriptan. These findings may reflect the more rapid and consistent absorption of sumatriptan using AVP-825. Increased WPV with AVP-825 in the first 15 minutes likely reflects the earlier onset of treatment effects with the device compared to oral sumatriptan. LSMEMs show promise as a novel approach for assessing and comparing consistency of treatment response in migraine trials. PMID: 31062349 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31062349?dopt=Abstract

Source: Headache - May 6, 2019 Category: Neurology Authors: McGinley JS, Buse DC, Shulman KJ, Wirth RJ, Hugentobler E, Lipton RB Tags: Headache Source Type: research